Matches in Wikidata for { <http://www.wikidata.org/entity/Q90751086> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q90751086 description "2019 թվականին հրատարակված գիտական հոդված" @default.
- Q90751086 description "article scientifique (publié 2019)" @default.
- Q90751086 description "articolo scientifico (pubblicato il 2019)" @default.
- Q90751086 description "artigo científico (publicado na 2019)" @default.
- Q90751086 description "artikull shkencor i botuar më 01 janar 2019" @default.
- Q90751086 description "artículo científico publicado en 2019" @default.
- Q90751086 description "artículu científicu espublizáu en xineru de 2019" @default.
- Q90751086 description "im Jahr 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90751086 description "scientific article published on 01 January 2019" @default.
- Q90751086 description "wetenschappelijk artikel" @default.
- Q90751086 description "наукова стаття, опублікована 1 січня 2019" @default.
- Q90751086 description "научна статия" @default.
- Q90751086 name "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 name "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 name "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 type Item @default.
- Q90751086 label "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 label "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 label "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 prefLabel "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 prefLabel "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 prefLabel "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 P1433 Q90751086-69CA8F8A-E00D-417B-95B0-9D77C0F669CD @default.
- Q90751086 P1476 Q90751086-8E206B24-B7A3-4143-92F2-A7D59805EDCA @default.
- Q90751086 P2093 Q90751086-03E7F93C-32F8-44B5-B754-C5D4AFCF91B6 @default.
- Q90751086 P2093 Q90751086-06E999CE-B3C2-4238-80AF-540944B42743 @default.
- Q90751086 P2093 Q90751086-0DD32D0B-13DB-4910-AD62-B8191232DCEF @default.
- Q90751086 P2093 Q90751086-12A3B25B-17EB-447B-AD8F-FD9F33A25F43 @default.
- Q90751086 P2093 Q90751086-31DF898C-3985-4F9E-A20D-4DBDE02294B5 @default.
- Q90751086 P2093 Q90751086-4A7039BB-4317-4EFC-82AC-8117DB7B1302 @default.
- Q90751086 P2093 Q90751086-6A2FF766-3DA9-469E-8109-CC9263FF32DE @default.
- Q90751086 P2093 Q90751086-8F2B0A7A-E4D4-4AD8-AC69-8BE3EFEC7677 @default.
- Q90751086 P2093 Q90751086-936B55F2-8C37-443F-BB82-BF110A29E8B6 @default.
- Q90751086 P2093 Q90751086-9F459B1D-D2DC-4AAC-B11A-10414B02F20D @default.
- Q90751086 P2093 Q90751086-A0DDA8DD-8A62-473D-A1DE-1EDB904C2D4A @default.
- Q90751086 P2093 Q90751086-ADDDAA2F-CBDC-4930-BEFD-DB85B0EDBF98 @default.
- Q90751086 P2093 Q90751086-D3D0B2A0-2A06-4844-A3BF-D098838D5363 @default.
- Q90751086 P2093 Q90751086-DCD42033-CA6A-4F8B-A350-C7393D5B5C36 @default.
- Q90751086 P2093 Q90751086-E869D1CB-2A92-49AC-A7A1-6EB99F3223FE @default.
- Q90751086 P2093 Q90751086-F11D24E8-AC39-41B7-9AF9-C0B88F4BF588 @default.
- Q90751086 P304 Q90751086-8286B09F-2F7D-46DF-A8A3-A9F5FF47BB0D @default.
- Q90751086 P31 Q90751086-4F18FF9A-7FA2-4F91-8D9F-A4C0E832B4A2 @default.
- Q90751086 P356 Q90751086-87C7B315-7BE1-4F5F-87DE-3558C47B2FD6 @default.
- Q90751086 P433 Q90751086-255F110C-5DFB-445E-9460-680BB50DDD3C @default.
- Q90751086 P478 Q90751086-723B617F-8EBD-4471-AE20-AB0A0E6CC799 @default.
- Q90751086 P577 Q90751086-E3312D6A-BDFE-4612-A574-0666CCA2D9CD @default.
- Q90751086 P698 Q90751086-ED75862A-0BD2-4C66-9870-15D7399AED2F @default.
- Q90751086 P921 Q90751086-43913CEA-8ADC-4196-9C1D-027A5E73C4DF @default.
- Q90751086 P356 J.JURO.2018.07.065 @default.
- Q90751086 P698 30076904 @default.
- Q90751086 P1433 Q15709979 @default.
- Q90751086 P1476 "Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS" @default.
- Q90751086 P2093 "Andrew Wagner" @default.
- Q90751086 P2093 "Anna V Faino" @default.
- Q90751086 P2093 "Atreya Dash" @default.
- Q90751086 P2093 "Daniel W Lin" @default.
- Q90751086 P2093 "Ian M Thompson" @default.
- Q90751086 P2093 "James D Brooks" @default.
- Q90751086 P2093 "James T Kearns" @default.
- Q90751086 P2093 "Jeanette M Schenk" @default.
- Q90751086 P2093 "Lisa F Newcomb" @default.
- Q90751086 P2093 "Martin E Gleave" @default.
- Q90751086 P2093 "Michael Fabrizio" @default.
- Q90751086 P2093 "Peter R Carroll" @default.
- Q90751086 P2093 "Peter S Nelson" @default.
- Q90751086 P2093 "Todd M Morgan" @default.
- Q90751086 P2093 "William J Ellis" @default.
- Q90751086 P2093 "Yingye Zheng" @default.
- Q90751086 P304 "106-111" @default.
- Q90751086 P31 Q13442814 @default.
- Q90751086 P356 "10.1016/J.JURO.2018.07.065" @default.
- Q90751086 P433 "1" @default.
- Q90751086 P478 "201" @default.
- Q90751086 P577 "2019-01-01T00:00:00Z" @default.
- Q90751086 P698 "30076904" @default.
- Q90751086 P921 Q110324059 @default.